natgillin/translations-raw huggingface dataset:
Studies in rats have shown excretion of brivaracetam in breast milk (see section 5.3). 
Študije na podganah so pokazale izločanje brivaracetama v materino mleko (glejte poglavje 5.3).
EU/1/15/1073/001 EU/1/15/1073/002 EU/1/15/1073/003 EU/1/15/1073/004 EU/1/15/1073/005 EU/1/15/1073/006 EU/1/15/1073/007 EU/1/15/1073/008 EU/1/15/1073/009 EU/1/15/1073/010 EU/1/15/1073/011 EU/1/15/1073/012 EU/1/15/1073/013 EU/1/15/1073/014 EU/1/15/1073/015 EU/1/15/1073/016 EU/1/15/1073/017 EU/1/15/1073/018 EU/1/15/1073/019 EU/1/15/1073/020 EU/1/15/1073/023 EU/1/15/1073/024 EU/1/15/1073/025 EU/1/15/1073/026 EU/1/15/1073/027 
EU/1/15/1073/001 EU/1/15/1073/002 EU/1/15/1073/003 EU/1/15/1073/004 EU/1/15/1073/005 EU/1/15/1073/006 EU/1/15/1073/007 EU/1/15/1073/008 EU/1/15/1073/009 EU/1/15/1073/010 EU/1/15/1073/011 EU/1/15/1073/012 EU/1/15/1073/013 EU/1/15/1073/014 EU/1/15/1073/015 EU/1/15/1073/016 EU/1/15/1073/017 EU/1/15/1073/018 EU/1/15/1073/019 EU/1/15/1073/020 EU/1/15/1073/023 EU/1/15/1073/024 EU/1/15/1073/025 EU/1/15/1073/026
Brivaracetam may increase plasma concentrations of medicinal products metabolised by CYP2C19 (e.g. lanzoprazole, omeprazole, diazepam). 
Brivaracetam lahko poveča plazemske koncentracije učinkovin, ki se presnavljajo s CYP2C19 (npr. lansoprazol, omeprazol, diazepam).
Do not use Briviact if: - you are allergic to brivaracetam, other pyrrolidone derivatives or any of the other ingredients of this medicine (listed in section 6). 
Ne jemljite zdravila Briviact: - če ste alergični na brivaracetam, druge derivate pirolidona ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
The hydroxyacid metabolite did not reveal any safety concerns in non clinical studies. 
Hidroksikislinski presnovek v predkliničnih študijah ni pokazal nobenih varnostnih zadržkov.
Brivaracetam was administered at weekly increasing doses of approximately 1 mg/kg/day, 2 mg/kg/day, and 4 mg/kg/day. 
Brivaracetam so dajali v tedensko naraščajočih odmerkih približno 1 mg/kg/dan, 2 mg/kg/dan in 4 mg/kg/dan.
In clinical studies, a reduction in seizure frequency over placebo was higher with the dose of 100 mg/day than with 50 mg/day. 
V kliničnih študijah je bilo zmanjšanje pogostnosti napadov v primerjavi s placebom večje pri odmerku 100 mg/dan kot pri odmerku 50 mg/dan.
OUTER CARTON OF MULTIPACK (WITH BLUE BOX) 
ŠKATLA VEČKRATNEGA PAKIRANJA (Z MODRIM OKENCEM)
None a 
Nič a
Brivaracetam may also be initiated at 2 mg/kg/day based on physician assessment of need for seizure control. 
Brivaracetam je možno uvesti tudi z 2 mg/kg/dan na podlagi zdravnikove ocene potrebe po obvladovanju epileptičnih napadov.
Children who directly enrolled received a brivaracetam starting dose of 1 mg/kg/day and depending on response and tolerability, the dose was increased up to 5 mg/kg/day by doubling the dose at weekly intervals. 
Otroci, ki so bili vključeni neposredno, so prejemali začetni odmerek brivaracetama 1 mg/kg/dan; odvisno od odziva in prenašanja so odmerek povečali do 5 mg/kg/dan s podvajanjem odmerka v tedenskih intervalih.
Two oral syringes will be provided in the carton. 
V škatli sta priloženi dve peroralni brizgi.
Brivaracetam is eliminated primarily by metabolism and by excretion in the urine. 
Brivaracetam se primarno izloča s presnovo in izločanjem z urinom.
AUC 19 % ↓ No dose adjustment required 
AUC 19 % ↓ Prilagoditev odmerka ni potrebna.
Multipack: 168 (3 packs of 56) film-coated tablets 
Večkratno pakiranje: 168 (3 pakiranja po 56) filmsko obloženih tablet
The steady-state plasma clearance of brivaracetam was similar (0.76 ml/min/kg) to young healthy male subjects (0.83 ml/min/kg) (see section 4.2). 
Plazemski očistek brivaracetama v stanju dinamičnega ravnovesja je bil podoben (0,76 ml/min/kg) kot pri mladih zdravih moških preskušancih (0,83 ml/min/kg) (glejte poglavje 4.2).
Contains sodium acetate (trihydrate), sodium chloride. 
Vsebuje natrijev acetat (trihidrat), natrijev klorid.
INTERMEDIATE CARTON WITHIN MULTIPACK (3 PACKS OF 56 FILM-COATED TABLETS) (WITHOUT BLUE BOX) 
VMESNA ŠKATLA ZNOTRAJ VEČKRATNEGA PAKIRANJA (3 PAKIRANJA PO 56 FILMSKO OBLOŽENIH TABLET) (BREZ MODREGA OKENCA)
Syringe 10 ml and 5ml (as symbols - only for the outer carton) 
Brizga 10 ml in 5 ml (v obliki simbola - samo za škatlo)
- At the request of the European Medicines Agency; 
Posodobljen RMP je treba predložiti: • na zahtevo Evropske agencije za zdravila;
The most frequently reported adverse reactions (>10 %) with brivaracetam treatment were: somnolence (14.3 %) and dizziness (11.0 %). 
Najpogosteje poročana neželena učinka (> 10 %) pri zdravljenju z brivaracetamom sta bila somnolenca (14,3 %) in omotica (11,0 %).
Effects of brivaracetam on other medicinal products Brivaracetam given 50 or 150 mg/day did not affect the AUC of midazolam (metabolised by CYP3A4). 
Brivaracetam v odmerku 50 ali 150 mg/dan ni vplival na AUC midazolama (ki ga presnavlja CYP3A4).
Brivaracetam may also be initiated at 100 mg/day based on physician assessment of need for seizure control. 
Brivaracetam je možno uvesti tudi s 100 mg/dan na podlagi zdravnikove ocene potrebe po obvladovanju epileptičnih napadov.
The 5 ml oral syringe has 2 overlapping graduations: in steps of 0.25 ml and in steps of 0.1 ml. 
5-ml peroralna odmerna brizga ima 2 prekrivajoči se graduaciji: v korakih po 0,25-ml in v korakih po 0,1 ml.
In adults, a 50 mg/day starting dose should be considered. 
Pri odraslih je treba razmisliti o začetnem odmerku 50 mg/dan.
Two oral syringes (5 ml and 10 ml) are included in the carton. 
V škatli sta priloženi dve peroralni brizgi (5 ml in 10 ml).
- Periodic safety update reports 
• Redno posodobljena poročila o varnosti zdravila (PSUR)
- You can switch between taking Briviact orally to the solution for injection/infusion, and the other way around. 
- Lahko prehajate iz peroralnega jemanja zdravila Briviact na raztopino za injiciranje in obratno.
Any unused medicinal product, neat or diluted, or waste material should be disposed of in accordance with local requirements. 
Neuporabljeno zdravilo (nerazredčeno ali razredčeno) ali odpadni material zavrzite v skladu z lokalnimi predpisi.
Therapeutic dose range 
Razpon terapevtskega odmerka
- The recommended dose is from 0.5 mg to 2 mg for each kg of bodyweight, taken twice a day. 
- Priporočeni odmerek je od 0,5 mg do 2 mg za vsak kg telesne mase dvakrat na dan.
Talk to your doctor or pharmacist before taking Briviact if: - You have thoughts of harming or killing yourself. 
Pred jemanjem zdravila Briviact se posvetujte z zdravnikom ali farmacevtom če: - razmišljate o samopoškodovanju ali samomoru.
In a third study, a pre-specified analysis demonstrated efficacy over placebo for 100 mg/day and 200 mg/day in patients with prior exposure to levetiracetam. 
V tretji študiji, je vnaprej specificirana analiza pokazala učinkovitost v primerjavi s placebom za 100 mg/dan in 200 mg/dan pri bolnikih, ki so bili prej izpostavljeni levetiracetamu.
Brivaracetam did not show any dependence potential in rats. 
Brivaracetam pri podganah ni kazal potenciala za razvoj odvisnosti.
AUC 21 % ↓ No dose adjustment required 
AUC 21 % ↓ Prilagoditev odmerka ni potrebna.
The recommended maintenance dose is 2 mg/kg/day. 
Priporočeni vzdrževalni odmerek je 2 mg/kg/dan.
Solution for injection/infusion (injection/infusion) Clear, colourless, solution. 
raztopina za injiciranje/infundiranje (injekcija/infuzija) Bistra, brezbarvna raztopina.
Although the number of subjects is limited, there was no observed benefit of brivaracetam versus placebo in patients taking levetiracetam concurrently which may reflect competition at the SV2A binding site. 
Čeprav je bilo število preskušancev omejeno, niso opazili prednosti brivaracetama v primerjavi s placebom pri bolnikih, ki so sočasno jemali levetiracetam, kar lahko odraža konkurenco na mestu vezave SV2A.
Follow these steps the first time you take Briviact: - Take off the adaptor from the oral syringe (figure 2). 
Ko prvič vzamete zdravilo Briviact, upoštevajte naslednje korake: - Snemite adapter s peroralne brizge (slika 2).
In a study in elderly subjects (65 to79 years old; with creatinine clearance 53 to 98 ml/min/1.73 m²) receiving brivaracetam 400 mg/day in bid administration, the plasma half-life of brivaracetam was 7.9 hours and 9.3 hours in the 65 to 75 and >75 years groups, respectively. 
V študiji pri starejših preiskovancih (starih od 65 do 79 let, očistek kreatinina od 53 do 98 ml/min/1,73 m²), ki so prejemali brivaracetam v odmerku 400 mg/dan dvakrat na dan, je bil plazemski razpolovni čas brivaracetama 7,9 oziroma 9,3 ure v skupinah od 65 do 75 oziroma > 75 let.
The 10 ml oral syringe has only one graduation in steps of 0.25 ml. 
10-ml peroralna odmerna brizga ima samo eno graduacijo v korakih po 0,25 ml.
The main disposition pathway of brivaracetam is by CYP-independent hydrolysis. 
Glavna presnovna pot brivaracetama je od CYP neodvisna hidroliza.
The percentages of patients with at least a 50 % reduction in seizure frequency were 20.3 %, 34.2 %, 39.5 %, and 37.8 % for placebo, 50 mg/day, 100 mg/day, and 200 mg/day, respectively. 
Odstotek bolnikov z vsaj 50 % zmanjšanjem pogostnosti napadov je bil 20,3 %, 34,2 %, 39,5 % in 37,8 % za placebo, 50 mg/dan, 100 mg/dan in 200 mg/dan.
Of the 130 elderly subjects enrolled in the brivaracetam phase 2/3 development program (44 with epilepsy), 100 were 65-74 years of age and 30 were 75-84 years of age. 
faze (44 od teh z epilepsijo), je bilo 100 starih 65-74 let, 30 pa 75-84 let.
How long to take Briviact for 
Kako dolgo jemati zdravilo Briviact
In a pooled analysis of the three pivotal trials, no differences in efficacy (measured as 50 % responder rate) was observed within the dose range of 50 mg/day to 200 mg/day when brivaracetam is combined with inducing or non-inducing AEDs. 
V združeni analizi treh ključnih preskušanj niso opazili sprememb učinkovitosti (merjeno kot 50 % stopnja odzivnosti) v razponu odmerkov od 50 mg/dan do 200 mg/dan, če je bil brivaracetam kombiniran z antiepileptiki, ki inducirajo ali ne inducirajo encimov.
In vitro, brivaracetam did ot induce CYP1A2. 
In vitro brivaracetam ni induciral CYP1A2.
Animal studies did not detect any teratogenic potential of brivaracetam (see section 5.3). 
V študijah na živalih niso zaznali teratogenega potenciala brivaracetama (glejte poglavje 5.3).
Intravenous bolus: may be administered directly without dilution Intravenous infusion: may be administered over 15 minutes in a compatible diluent 
intravenski bolus: lahko dajete neposredno brez redčenja; intravenska infuzija: lahko razredčite s kompatibilnim topilom in dajete kot 15-minutno intravensko infuzijo.
300 ml amber glass bottle (type III) with a white child resistant closure (polypropylene) in a box also containing a 5 ml and 10 ml graduated oral dosing syringe (polypropylene, polyethylene) and an adaptor for the syringe (polyethylene). 
300 ml steklenica (tip III) jantarne barve z belo zaporko, varno za otroke (polipropilen) v škatli, ki vsebuje še 5 ml in 10 ml graduirano brizgo za peroralno odmerjanje (polipropilen, polietilen) in adapter za brizgo (polietilen).
There is no data on placental transfer in humans, but brivaracetam was shown to readily cross the placenta in rats (see section 5.3). 
Ni podatkov o prehajanju skozi placento pri ljudeh, vendar je bilo pri podganah dokazano, da brivaracetam zlahka prehaja skozi placento (glejte poglavje 5.3).
CYP2B6 induction has not been investigated in vivo and brivaracetam may decrease plasma concentrations of medicinal products metabolised by CYP2B6 (e.g. efavirenz). 
In vivo indukcije CYP2B6 niso preučevali in brivaracetam lahko zmanjša plazemske koncentracije učinkovin, ki se presnavljajo s CYP2B6 (npr. efavirenz).
As from the 0.1 ml graduation mark, each graduation corresponds to 0.1 ml which is 1 mg of brivaracetam. 
Od graduacijske oznake 0,1 ml naprej vsaka graduacijska oznaka ustreza 0,1 ml, kar je 1 mg brivaracetama.
Brivaracetam may be initiated with either intravenous or oral administration. 
Zdravljenje z brivaracetamom lahko začnemo z intravensko ali peroralno uporabo.
No clinical data are available in paediatric patients with hepatic impairment. 
Klinični podatki za pediatrične bolnike z okvaro jeter niso na voljo.
• Packs of 14, 56 film-coated tablets and in multipacks containing 168 (3 packs of 56) filmcoated tablets in PVC/PCTFE - Aluminium blisters 
• Pakiranje po 14, 56 filmsko obloženih tablet in v večkratnem pakiranju, ki vsebuje 168 (3 pakiranja po 56) filmsko obloženih tablet v pretisnih omotih PVC/PCTFE-aluminij.
In vitro, the hydroxylation of brivaracetam is mediated primarily by CYP2C19. 
Hidroksilacija brivaracetama in vitro je primarno posredovana s CYP2C19.
There were no adverse effects on CNS function, neuropathological and brain histopathological examination. 
Neželenih učinkov na delovanje centralnega živčnega sistema ni bilo, prav tako niso bili opaženi pri nevropatoloških in histopatoloških preiskavah možganov.
Further seizure frequency reduction is obtained by increasing the dose to 100 mg/day and reaches a plateau at 200 mg/day. 
Nadaljnje zmanjšanje pogostnosti epileptičnih napadov je bilo doseženo s povečanjem odmerka na 100 mg/dan in doseže konstantno raven pri 200 mg/dan.
Adverse reactions with intravenous administration generally appeared to be similar to those observed with oral administration. 
Neželeni učinki pri intravenski uporabi so bili v splošnem podobni tistim, ki so jih opazili pri peroralni uporabi.
Reactions suggestive of immediate (Type I) hypersensitivity have been reported in a small number of brivaracetam patients (9/3022) during clinical development. 
Med kliničnim razvojem zdravila so pri majhnem številu bolnikov, ki so jemali brivaracetam (9/3022) poročali o reakcijah, ki so kazale na takojšnjo preobčutljivost (tip I).
As in adults, brivaracetam solution for injection/infusion is an alternative route of administration for patients when oral administration is temporarily not feasible. 
Kot pri odraslih je raztopina brivaracetama za injiciranje/infundiranje alternativna pot dajanja bolnikom, ko peroralna uporaba ni izvedljiva.
In the clinical studies, although the numbers were limited, there was no observed benefit of brivaracetam versus placebo in patients taking levetiracetam concurrently. 
V kliničnih študijah, kljub njihovemu omejenemu številu, niso opazili koristi brivaracetama v primerjavi s placebom pri bolnikih, ki so sočasno jemali levetiracetam.
Briviact may be diluted with the following solutions: sodium chloride 9 mg/ml (0.9 %), glucose 50 mg/ml (5 %) solution for injection or lactated Ringer's solution. 
Zdravilo Briviact lahko razredčite z naslednjimi raztopinami: natrijev klorid 9 mg/ml (0,9 %), glukoza 50 mg/ml (5 %) raztopina za injiciranje ali Ringerjeva raztopina z laktatom.
In vitro, Brivaracetam inhibits OAT3 with a half maximal inhibitory concentration 42-fold higher than the Cmax at the highest clinical dose. 
Brivaracetam zavira OAT3 s polovico največje zaviralne koncentracije, ki je 42-krat večja kot Cmax pri največjem kliničnem odmerku.
Briviact contains lactose 
Zdravilo Briviact vsebuje laktozo
briviact 10 mg/ml (Only for outer carton) 
briviact 10 mg/ml (Samo za škatlo.)
No human data on the effect of brivaracetam on fertility are available. 
O vplivu brivaracetama na plodnost pri ljudeh ni podatkov.
Contains croscarmellose sodium, lactose monohydrate and lactose anhydrous. 
Vsebuje premrežen natrijev karmelozat, laktozo monohidrat in brezvodno laktozo.
Co-administration of brivaracetam (100 mg/day) with an oral contraceptive containing ethinylestradiol (0.03 mg) and levonorgestrel (0.15 mg) did not influence the pharmacokinetics of either substance. 
Sočasno dajanje brivaracetama (100 mg/dan) in peroralnih kontraceptivov, ki so vsebovali etinilestradiol (0,03 mg) in levonorgestrel (0,15 mg), ni vplivalo na farmakokinetiko nobene od učinkovin.
Antiepileptic drugs 
Antiepileptiki
Findings not observed in clinical studies, but seen in the repeated-dose toxicology dog studies at exposure similar to the clinical plasma AUC, were hepatotoxic effects (mainly porphyria). 
Pri študijah toksikologije s ponavljajočimi se odmerki pri psih, z izpostavljenostjo podobno klinični plazemski AUC, so ugotovili hepatotoksične učinke (predvsem porfirijo), vendar tega v kliničnih študijah niso opazili.
Brivaracetam solution for injection/infusion is an alternative for patients when oral administration is temporarily not feasible. 
Raztopina brivaracetama za injiciranje/infundiranje je alternativa za bolnike, ko peroralno dajanje začasno ni mogoče.
There are limited clinical data on the use of brivaracetam in patients with pre-existing hepatic impairment. 
Kliničnih podatkov o uporabi brivaracetama pri bolnikih z obstoječo okvaro jeter ni veliko.
Currently, no clinical data are available in neonates. 
Trenutno kliničnih podatkov za novorojenčke ni na voljo.
The recommended maintenance dose is 100 mg/day. 
Priporočeni vzdrževalni odmerek je 100 mg/dan.
The other ingredients are: sodium acetate (trihydrate), acetic acid, glacial, sodium chloride, water for injection. 
Druge sestavine zdravila so: natrijev acetat (trihidrat), koncentrirana ocetna kislina (ledocet), natrijev klorid, voda za injekcije.
When brivaracetam was coadministered at a dose of 400 mg/day (twice the recommended maximum daily dose) with an oral contraceptive containing ethinylestradiol (0.03 mg) and levonorgestrel (0.15 mg), a reduction in estrogen and progestin AUCs of 27 % and 23 %, respectively, was observed without impact on suppression of ovulation. 
Pri sočasnem dajanju brivaracetama v odmerku 400 mg/dan (dvakratni največji priporočeni dnevni odmerek) s peroralnimi kontraceptivi, ki so vsebovali etinilestradiol (0,03 mg) in levonorgestrel (0,15 mg), so opazili zmanjšanje AUC za estrogen in progestin za 27 % oz. 23 %, vendar to ni vplivalo na zaustavitev ovulacije.
The solution for injection/infusion contains 0.83 mmol (or 19.14 mg) sodium per vial. 
Raztopina za injiciranje/infundiranje vsebuje 0,83 mmol (ali 19,14 mg) natrija na vialo.
Based on individual patient response, the dose may be adjusted in the effective dose range of 1 mg/kg/day and 4 mg/kg/day. 
Na podlagi odziva posameznega bolnika je mogoče odmerek prilagajati v razponu učinkovitega odmerka 1 mg/ kg/dan in 4 mg/kg/dan.
The minimum extractible volume is 0.25 ml which is 2.5 mg of brivaracetam. 
Najmanjša količina, ki jo je mogoče izvleči, je 0,25 ml, kar pomeni 2,5 mg brivaracetama.
None a based on a study involving the administration of a supratherapeutic dose of 400 mg/day brivaracetam 
Nič a temelji na študiji, ki vključuje dajanje brivaracetama, kot supraterapevtskega odmerka 400 mg/dan Karbamazepin
UCB Pharma S.A., Chemin du Foriest, B-1420 Braine-l'Alleud, Belgium. 
UCB Pharma S.A., Chemin du Foriest, B-1420 Braine-l'Alleud, Belgija
From entry into the randomized studies,5.3 % of the subjects exposed to brivaracetam for 6 months (n=1,500) were seizure free compared to 4.6 % and 3.7 % for subjects exposed for 12 months (n=1,188) and 24 months (n=847), respectively. 
Od začetka sodelovanja v randomiziranih študijah je bilo 5,3 % preskušancev, ki so bili izpostavljeni brivaracetamu 6 mesecev (n=1500), brez napadov, v primerjavi s 4,6 % oziroma 3,7 % za preskušance, ki so bili izpostavljeni 12 mesecev (n=1188) oziroma 24 mesecev (n=847).
Briviact solution for injection/infusion contains 0.83 mmol (or 19.14 mg) sodium per vial. 
Zdravilo Briviact raztopina za injiciranje/infundiranje vsebuje 0,83 mmol (ali 19,14 mg) natrija na vialo.
Somnolence and fatigue (8.2 %) were reported at a higher incidence with increasing dose. 
Z večanjem odmerka so poročali o povečani incidenci somnolence in utrujenosti (8,2 %).
In vitro studies have shown that brivaracetam exhibits little or no inhibition of CYP450 isoforms except for CYP2C19. 
Študije in vitro so pokazale, da brivaracetam malo zavira ali ne zavira, izooblike CYP450 razen CYP2C19.
Oral dosing syringe (10 ml graduated every 0.25 ml) with an adaptor, recommended for use by patients weighing more than 20 kg or needing a dose between 50 mg and 100 mg (5 ml to 10 ml) brivaracetam per administration. 
Peroralna odmerna brizga (10 ml graduirana na vsaki 0,25 ml) z adapterjem se priporoča za uporabo pri bolnikih s telesno maso več kot 20 kg ali bolnikih, ki potrebujejo odmerek med 50 mg in 100 mg (5 ml do 10 ml) brivaracetama na dajanje.
Take the daily dose in two equal divided doses - one in the morning and one in the evening at about the same time each day. 
Dnevni odmerek vzemite razdeljen na dva enaka odmerka - enega zjutraj in enega zvečer, vsak dan ob približno enakem času.
Allée de la Recherche 60 (address only for outer carton) B-1070 Brussels 
Allée de la Recherche 60 (naslov samo za škatlo) B-1070 Brussels
1 mg/kg/day (or 2 mg/kg/day)* 
1 mg/kg/dan (ali 2 mg/kg/dan)*
Dose taken twice daily for children from 4 years of age weighing less than 50 kg. 
Odmerek se jemlje dvakrat na dan za otroke od 4 leta starosti,
A 40 % decrease in steady-state plasma concentration has been estimated across a body weight range from 46 kg to 115 kg. 
Pri razponu telesne mase od 46 do 115 kg so ocenili približno 40 % zmanjšanje plazemske koncentracije v dinamičnem ravnovesju.
Convulsion, vertigo 
Konvulzije, vrtoglavica
Contains sodium citrate, carmellose sodium, methyl parahydroxybenzoate (E218), sorbitol liquid and glycerol (E422). 
Vsebuje natrijev citrat, natrijev karmelozat, metilparahidroksibenzoat (E218), tekoči sorbitol in glicerol (E422).
It is recommended to parent and care giver to administer Briviact oral solution with the measuring device (10 ml or 5 ml oral dosing syringe) provided in the carton box. 
Priporoča se, da starš ali negovalec zdravilo Briviact peroralno raztopino aplicira z merilnim pripomočkom, priloženim v škatli (peroralna odmerna brizga z 10 ml ali 5 ml).
Treatment of an overdose should include general supportive measures. 
Specifičnega antidota za preveliko odmerjanje brivaracetama ni. Zdravljenje prevelikega odmerka naj vključuje splošne podporne ukrepe.
Briviact 10 mg/ml solution for injection/infusion 5 ml vial is packed in a carton box of 10 vials. 
Zdravilo Briviact 10 mg/ml raztopina za injiciranje/infundiranje je na voljo v 5 ml vialah, v škatli s po 10 vialami.
Improvement in the median percent reduction in seizure frequency per 28 days has been observed in patients with type IC seizure (secondary generalized tonic-clonic seizures) at baseline treated with brivaracetam (66.6 % (n=62), 61.2 % (n=100) and 82.1 % (n=75) of the patients on brivaracetam 50 mg/day, 100 mg/day and 200 mg/day respectively as compared to placebo 33.3 % (n=115)). 
Pri bolnikih z napadi tipa IC (sekundarni generalizirani tonično-klonični napadi), zdravljenih z brivaracetamom, so v primerjavi z izhodiščem opazili izboljšanje v mediani odstotka zmanjšanja pogostnosti napadov na 28 dni (pri 66,6 % (n=62), 61,2 % (n=100) in 82,1 % (n=75) bolnikov, ki so prejemali 50 mg/dan, 100 mg/dan in 200 mg/dan, v primerjavi s 33,3 % (n=115) bolnikov, ki so prejemali placebo).
The medicine is injected slowly into your vein or given as an infusion (drip) over 15 minutes. 
Zdravilo boste prejeli s počasnim injiciranjem v žilo ali pa s 15-minutnim infundiranjem (s kapanjem).
• Packs of 14 x 1 and 100 x 1 film-coated tablet in PVC/PCTFE - Aluminium blisters 
• Pakiranje po 14 x 1 in 100 x 1 filmsko obložena tableta v pretisnih omotih PVC/PCTFEaluminij.
There is limited clinical experience with brivaracetam overdose in humans. 
Klinične izkušnje s prevelikim odmerjanjem brivaracetama pri ljudeh so omejene.
Brivaracetam film-coated tablets contain lactose. 
Filmsko obložene tablete brivaracetama vsebujejo laktozo.
Brivaracetam has not been studied in patients undergoing hemodialysis (see section 4.2). 
Brivaracetama pri bolnikih, ki so na hemodializi, niso preučevali (glejte poglavje 4.2).
If you are not sure, talk to your doctor or pharmacist before taking Briviact. 
Če niste prepričani, se pred jemanjem zdravila Briviact posvetujte z zdravnikom ali farmacevtom.
- Do not drive, cycle or use any tools or machines until you know how the medicine affects you. 
- Dokler ne veste, kako to zdravilo vpliva na vas, ne smete voziti avtomobila ali kolesa oziroma upravljati z orodji ali stroji.